Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre, E; Vergote, I; Anderson, R; Coens, C; Katsaros, D; Hirsch, Fr; Boeckx, B; Varella-Garcia, M; Ferrero, A; Ray-Coquard, I; Green, Ja; Steer, C; Emjj, Berns; Casado, A; Lambrechts, D; Jimeno, A

doi:10.1007/s11523-016-0433-x

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre E;Vergote I;Anderson R;Coens C;Katsaros D;Hirsch FR;Boeckx B;Varella-Garcia M;Ferrero A;Ray-Coquard I;Green JA;Steer C;Berns EMJJ;Casado A;Lambrechts D;Jimeno A

2016-01-01

Scheda breve

Scheda completa

Scheda completa (DC)

	Anno
	
				2016
			
	Titolo rivista
	
				TARGETED ONCOLOGY
			
	N. Volume
	
				11
			
	Fascicolo
	
				3
			
	Pagine (da)
	
				429
			
	Pagine (a)
	
				429
			
	DOI
	
				https://dx.doi.org/10.1007/s11523-016-0433-x
			
	Tutti gli autori
	
						Despierre E; Vergote I; Anderson R; Coens C; Katsaros D; Hirsch FR; Boeckx B; Varella-Garcia M; Ferrero A; Ray-Coquard I; Green JA; Steer C; Berns EMJ...espandi
						
	Appare nelle tipologie:
	
				03A-Articolo su Rivista

File in questo prodotto:

File	Dimensione	Formato
Tarceva EGFR Erratum.pdf Accesso aperto Tipo di file: PDF EDITORIALE Dimensione 244.94 kB Formato Adobe PDF Visualizza/Apri	244.94 kB	Adobe PDF	Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1904379

Citazioni

ND

2

1

CINECA IRIS Institutional Research Information System

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre E;Vergote I;Anderson R;Coens C;Katsaros D;Hirsch FR;Boeckx B;Varella-Garcia M;Ferrero A;Ray-Coquard I;Green JA;Steer C;Berns EMJJ;Casado A;Lambrechts D;Jimeno A

2016-01-01

Scheda breve

Scheda completa

Scheda completa (DC)

Citazioni

social impact

CINECA IRIS Institutional Research Information System

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre E;Vergote I;Anderson R;Coens C;Katsaros D;Hirsch FR;Boeckx B;Varella-Garcia M;Ferrero A;Ray-Coquard I;Green JA;Steer C;Berns EMJJ;Casado A;Lambrechts D;Jimeno A

2016-01-01

Scheda breve Scheda completa Scheda completa (DC)

Informazioni

Citazioni

social impact

Conferma cancellazione

Scheda breve

Scheda completa

Scheda completa (DC)